Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210


Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient.

Kingery L, Martin ML, Naegeli AN, Khan S, Viktrup L.

Int J Clin Pract. 2012 Sep;66(9):883-90. doi: 10.1111/j.1742-1241.2012.02960.x.


Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.

Fujimura T, Kume H, Nishimatsu H, Sugihara T, Nomiya A, Tsurumaki Y, Miyazaki H, Suzuki M, Fukuhara H, Enomoto Y, Homma Y.

BJU Int. 2012 May;109(10):1512-6. doi: 10.1111/j.1464-410X.2011.10445.x.


Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.

Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.

BJU Int. 2008 Nov;102(9):1133-9. doi: 10.1111/j.1464-410X.2008.07761.x.


An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.

Li MK, Garcia L, Patron N, Moh LC, Sundram M, Leungwattanakij S, Pripatnanont C, Cheng C, Chi-Wai M, Loi-Cheong N.

BJU Int. 2008 Jan;101(2):197-202.


Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being.

Eckhardt MD, van Venrooij GE, van Melick HH, Boon TA.

J Urol. 2001 Aug;166(2):563-8.


Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Rosen RC, Fitzpatrick JM; ALF-LIFE Study Group..

BJU Int. 2009 Oct;104(7):974-83. doi: 10.1111/j.1464-410X.2009.08503.x.


Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

McVary KT, Rademaker A, Lloyd GL, Gann P.

J Urol. 2005 Oct;174(4 Pt 1):1327-433.


Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team..

Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005.


Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.

Yoshida M, Sugiyama Y, Masunaga K, Maeda Y, Satoji Y, Nagata T, Inadome A.

Drugs Today (Barc). 2007 Jun;43 Suppl B:1-7.


Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.

Fukuta F, Masumori N, Mori M, Tsukamoto T.

BJU Int. 2012 Oct;110(7):1023-9. doi: 10.1111/j.1464-410X.2011.10866.x.


Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

Angalakuditi M, Seifert RF, Hayes RP, O'Leary MP, Viktrup L.

Health Qual Life Outcomes. 2010 Nov 12;8:131. doi: 10.1186/1477-7525-8-131.


Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society--Benign Prostatic Hyperplasia.

Donovan JL, Kay HE, Peters TJ, Abrams P, Coast J, Matos-Ferreira A, Rentzhog L, Bosch JL, Nordling J, Gajewski JB, Barbalias G, Schick E, Silva MM, Nissenkorn I, de la Rosette JJ.

Br J Urol. 1997 Nov;80(5):712-21.


Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.

BJU Int. 2003 Aug;92(3):262-6.


Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.

Carballido J, Fourcade R, Pagliarulo A, Brenes F, Boye A, Sessa A, Gilson M, Castro R.

Int J Clin Pract. 2011 Sep;65(9):989-96. doi: 10.1111/j.1742-1241.2011.02735.x.


A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.

Oudot A, Oger S, Behr-Roussel D, Caisey S, Bernabé J, Alexandre L, Giuliano F.

BJU Int. 2012 Nov;110(9):1352-8. doi: 10.1111/j.1464-410X.2012.11085.x.


Impact of lower urinary tract symptoms on discomfort in men aged between 50 and 80 years.

Robert G, Descazeaud A, Azzouzi R, Saussine C, Haillot O, Dumonceau O, Ballereau C, Fourmarier M, Devonec M, Lukacs B, Delongchamps NB, Desgrandchamps F, de la Taille A.

Urol Int. 2010;84(4):424-9. doi: 10.1159/000304509.


Supplemental Content

Support Center